Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

By Ward K. W.   Proksch J. W.   Azzarano L. M.   Mumaw J. A.   Roethke T. J.   Stelman G. J.   Walsh M. J.   Zeigler K. S.   McSurdy-Freed J. E.   Kehler J. R   Chokshi J.   Levy M. A.   Smith B. R.  

Xenobiotica, Vol. 31, Iss. 11, 2001-11 ,pp. : 783-797

Informa Healthcare

Access to resources Recommend Favorite

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: In vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man

By Ward K. W.   Proksch J. W.   Gorycki P. D.   Yu C.-P.   Ho M. Y. K.   Bush B. D.   Levy M. A.   Smith B. R.  

Xenobiotica, Vol. 32, Iss. 3, 2002-03 ,pp. : 235-250

Informa Healthcare

Access to resources Recommend Favorite

Pyridinylimidazole Compound SB 203580 Inhibits the Activity but Not the Activation of p38 Mitogen-Activated Protein Kinase

By Kumar S.   Jiang M.S.   Adams J.L.   Lee J.C.  

Biochemical and Biophysical Research Communications, Vol. 263, Iss. 3, 1999-10 ,pp. : 825-831

Elsevier

Access to resources Recommend Favorite

MAPKAPK5, a Novel Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase, Is a Substrate of the Extracellular-Regulated Kinase (ERK) and p38 Kinase

By Ni H.   Wang X.S.   Diener K.   Yao Z.  

Biochemical and Biophysical Research Communications, Vol. 243, Iss. 2, 1998-02 ,pp. : 492-496

Elsevier

Access to resources Recommend Favorite

Ceramide activates a mitochondrial p38 mitogen-activated protein kinase: A potential mechanism for loss of mitochondrial transmembrane potential and apoptosis

By Kong Jennifer   Klassen Shaun   Rabkin Simon  

Molecular and Cellular Biochemistry, Vol. 278, Iss. 1-2, 2005-10 ,pp. : 39-51

Springer Publishing Company

Access to resources Recommend Favorite